Ginsenoside Rg3 Attenuates Pulmonary Fibrosis by Inhibiting Endothelial to Mesenchymal Transition

Investigators hypothesized that Ginsenoside Rg3 may be a potential therapeutic agent for pulmonary fibrosis (PF)-targeting endothelial-to-mesenchymal transition (EndMT). EndMT occurred in the lung tissue of a bleomycin-induced PF mouse model, which was confirmed by co-staining of endothelial and mesenchymal markers in the pulmonary vasculature and changes in the expression of these markers.